Anti-Hypertensive Drugs - Sudan

Sudan

The Sudanese Anti-Hypertensive Drugs market is expected to witness a significant growth in revenue, projected to reach US$1.18m by the year 2024.
This growth is anticipated to continue with an annual growth rate (CAGR 2024-2029) of -1.94%, resulting in a market volume of US$1.07m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in this market, amounting to US$12,290.00m in the year 2024.
Sudan's anti-hypertensive drugs market is seeing a surge in demand due to the increasing prevalence of hypertension among its population.

Key regions: Japan, India, Italy, Brazil, South Korea

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Hypertensive Drugs market in Sudan has been experiencing steady growth in recent years.

Customer preferences: Sudan has a high prevalence of hypertension, which has led to an increase in demand for anti-hypertensive drugs. Customers in Sudan generally prefer affordable drugs that are effective in managing hypertension. This has led to a rise in the popularity of generic drugs in the market.

Trends in the market: The Anti-Hypertensive Drugs market in Sudan has been growing at a steady pace due to the increasing prevalence of hypertension in the country. The market is dominated by generic drugs, which are more affordable than branded drugs. This has led to stiff competition among drug manufacturers, resulting in a decrease in the prices of anti-hypertensive drugs.

Local special circumstances: Sudan is a low-income country, and the majority of the population cannot afford expensive drugs. This has led to an increase in the demand for generic drugs, which are more affordable. The government has also been taking steps to make healthcare more accessible to the population by subsidizing the cost of drugs.

Underlying macroeconomic factors: The Sudanese economy has been struggling due to years of political instability and economic sanctions. This has led to a decrease in the purchasing power of the population, making it difficult for them to afford expensive drugs. However, the government has been taking steps to improve the healthcare sector, which has led to an increase in the availability of drugs in the market. The government has also been working to improve the economy, which is expected to lead to an increase in the purchasing power of the population in the future.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.